The effect of administering a dopamine agonist (Cabergoline) on follicular and luteal development during pro-estrus and estrus in the female greyhound.
To study the effect of the dopamine agonist Cabergoline, on ovarian activity in the female dog during pro-estrus and estrus, 6 greyhounds were treated with 5 microg/kg per os of Cabergoline for 20 days beginning on the first day of pro-estrus; 6 animals were left untreated (controls). Ovarian morphology was determined by ultrasound examination once a day during pro-estrus and twice a day during estrus. Follicles were divided into three classes on the basis of their diameter: F1 (<3mm), F2 (3-6mm) and F3 (>6mm). The presence and diameters of post-ovulatory follicles (F-POST) and corpora lutea (CL) were also recorded. Blood samples were taken once a day during pro-estrus and twice a day during estrus. The plasma was assayed for LH, prolactin and progesterone by radioimmunoassay. There were no differences between Cabergoline-treated and control dogs in the duration of pro-estrus or estrus. There was a progressive increase in follicle diameter from the start of pro-estrus when follicles were mainly class F1 to the day of estrus when follicles were mainly class F3. Three days after the start of estrus, the first F-POST follicles were detected. This pattern of development continued and on day 5 the first CLs were detected. By day 9, only CLs were detected. The peak of pre-ovulatory LH was within 3 days of estrus and ovulation was detected in all animals within 3 days of the LH peak. There were no differences in LH concentrations between groups. Plasma prolactin levels varied between animals and were reduced in treated dogs, however, this was not statistically significant (P=0.12). Plasma progesterone levels were below 1.0 ng/ml before the LH surge and thereafter gradually increased. There were no differences in plasma progesterone concentrations between treated and control dogs. In conclusion these results show that the administration of the dopamine agonist Cabergoline during pro-estrus and estrus did not affect the duration of pro-estrus or estrus or the pattern of follicular and luteal development in female dogs.
De Rensis
F
F
Faculty of Veterinary Medicine, University of Parma, Italy. fabio.derensis@unipr.it
Spattini
G
G
Ballabio
R
R
Scaramuzzi
R J
RJ
D000818:Animals; D000077465:Cabergoline; D003338:Corpus Luteum / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000254:growth & development; D004285:Dogs / Q000502:physiology; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000494:pharmacology; D004873:Ergolines / Q000008:administration & dosage / Q000494:pharmacology*; D030762:Estrous Cycle / Q000097:blood / Q000187:drug effects*; D005260:Female; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D006080:Ovarian Follicle / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000254:growth & development; D010060:Ovulation / Q000097:blood / Q000187:drug effects; D011374:Progesterone / Q000097:blood; D011388:Prolactin / Q000097:blood; D014463:Ultrasonography
D018491:Dopamine Agonists; D004873:Ergolines; D011374:Progesterone; D011388:Prolactin; D007986:Luteinizing Hormone; D000077465:Cabergoline